
Yashpal Singh Malik
Deputy Director General (Agricultural Education)Indian Council of Agricultural Research, Headquarters, New Delhi , India

Submitted
2025/06/28First Online
2025/12/20doi
10.18805/IJAR.BF-2038Cite article - Jawaher J. Albaqami. (2025). Assessment of Anticancer Capacities of (Ceftriaxone/Zn) Drug Complex with Chemical Characterization against Three Cancer Cell Lines of Breast, Hepatic and Large Cell Lung Cancer (MCF-7; HepG-2; H460). Indian Journal of Animal Research. 59(12): 2046–2053. doi: 10.18805/IJAR.BF-2038
Background: Ceftriaxone (CF) shows high and wide range of the potent antibacterial activity with rare some side effects, a long half-life. Now new transition metal drug complex attract more attention for evolving of new capacities with multi-therapeutic approach such as anticancer activities.
Methods: CF/Zinc (CF/Zn) complex was prepared and characterized via the transmission and scanning electron microscope. CF/Zn complex was prepared in (1:1) ceftriaxone: Zn +2 ratio.
Result: (CF) coordinated as a tetradentate ligand towards zinc metal ion with the molecular formula [Zn(CF)(H 2 O) 2 ].2H 2 O.The particle size and morphological surface for zinc complex was examined by using of many analyses: SEM, EDX, TEM, TGA/DTG and X-ray diffraction. This study investigated the effect of CF/Zn metal complex as a potent anticancer agent against three cancer cell lines (Breast adenocarcinoma MCF-7, Hepatocellular carcinoma HepG-2 and large cell lung cancer H460). The synthesized complex showed great anticancer capacities against the three cell lines at conc. 10 ug/ml and the living percentages were: 95.44, 90.6 and 94.04 µg/ml respectively and inhibited the proliferation of the cancer cells at conc.100 ug/ml and the living percentages were 90.35, 80.25 and 84.26 µg/ml. Exposure to CF/Zn complex even at very low concentrations elevated anticancer capacities of CF against three dangerous and common cancer types worldwide.
Distinguished scholars and subject experts committed to editorial excellence, scientific integrity and rigorous peer review.
View Full Board